Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
Asian Markets Mixed as RBI Cuts Rates and BOJ Signals Possible Hike 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
South Korea's SK Chemicals has partnered with AstraZeneca's Korean affiliate in a contract manufacturing organization (CMO) agreement. SK Chemicals will produce and globally distribute Sidapvia, a new treatment for type 2 diabetes, combining leading active ingredients dapagliflozin and sitagliptin.
Under this agreement, SK Chemicals will be responsible for the manufacturing and global distribution of Sidapvia, a groundbreaking combination of Forxig (dapagliflozin) and sitagliptin. Sidapvia is indicated for adults aged 18 and older with type 2 diabetes, a condition characterized by improper insulin function and high blood sugar levels.
SK Chemicals and AstraZeneca have jointly developed this promising diabetes treatment. While SK Chemicals focuses on manufacturing and distribution, AstraZeneca will be the marketing authorization holder (MAH). They will handle country-specific licensing and marketing efforts, and South Korea has already granted licensing for Sidapvia, making it the first country to do so.
Sidapvia combines two active ingredients, Forxiga and sitagliptin, globally recognized as a leading SGLT-2 inhibitor and top-selling DPP-4 inhibitor. These ingredients work through different mechanisms of action to effectively lower blood glucose levels, offering a viable option for managing complications among diabetic patients.
Ahn Jae-hyun, the CEO of SK Chemicals, expressed utmost confidence in the company's pharmaceutical technology and production capabilities. These capabilities have paved the way for the supply of medicines to numerous countries, and Ahn emphasized the company's plans to foster diverse collaboration opportunities.
The collaboration between SK Chemicals and AstraZeneca began in early 2020, with AstraZeneca providing SK Chemicals with active pharmaceutical ingredients (APIs) and funding research for diabetes treatment development. Subsequently, SK Chemicals took over product research and development and conducted domestic clinical trials. With this new agreement as a starting point, SK Chemicals aims to expand the supply of Sidapvia in Korea and the global market.
This collaboration marks a significant milestone for SK Chemicals and AstraZeneca, solidifying their commitment to advancing diabetes treatment and improving the lives of millions of patients worldwide.
